In this randomized controlled trial, curcumin supplementation was used to treat beta-thalassemia (1). This double-blind randomized controlled clinical trial was performed on 61 β-thalassemia major patients. Subjects in the curcumin group received two 500 mg curcumin capsules daily and patients in the placebo group took 2 placebo capsules daily for 12 weeks. The results showed that serum malondialdehyde (MDA), total and direct bilirubin significantly decreased and total antioxidant capacity significantly increased in the curcumin group. The authors conclude that supplementation in combination with deferoxamin improved the antioxidant status in β-thalassemia major patients. Curcumin may be useful for the relief of metabolic complications in these patients.